Patent ID: 8513264

Claim:
A pharmaceutical composition comprising: (a) a GPR119 agonist of formula (10) (10), wherein one of X and Y is O and the other is N, R 1 is —SO 2 —C 1-3 alkyl, R 2 is H, F, Cl, or CH 3 , R 3 is H or CH 3 , and R 4 is C 2-5 alkyl; formula (11) (11), wherein one of X and Y is O and the other is N, R 1 is —CONHR 5 , R 2 is H, F, Cl, or CH 3 , R 3 is H or CH 3 , R 4 is C 2-5 alkyl, and R 5 is H, C 1-3 alkyl, or C 2-3 alkyl substituted by hydroxy, formula (12) (12), wherein one of X and Y is O and the other is N, R 1 is —CH 2 —SO 2 C 1-3 alkyl, R 2 is H, F, Cl, or CH 3 , R 3 is H or CH 3 , and R 4 is C 2-5 alkyl; formula (13) (13), wherein one of X and Y is O and the other is N, one of E and Q is N and the other is CH, R 1 is —SO 2 R 5 or —CONHR 6 , R 2 is H or CH 3 , R 3 is H or CH 3 , R 4 is C 2-5 alkyl, R 5 is C 1-3 alkyl, and R 6 is H, C 1-3 alkyl, or C 2-3 alkyl substituted by hydroxy; formula (14) (14), wherein one of X and Y is O and the other is N, R 1 is —SO 2 R 5 , —NR 6 R 7 , or —CONR 6 R 7 , R 2 is H or CH 3 , R 3 is H or CH 3 , R 4 is C 2-5 alkyl, R 5 is C 1-3 alkyl, R 6 is H, C 1-3 alkyl, or C 2-3 alkyl substituted by hydroxy, and R 7 is hydrogen, or formula (15) (15), 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine, or a pharmaceutically acceptable salt thereof; and (b) a DPP-4 inhibitor of wherein: R1 is ([1,5]naphthyridin-2-yl)methyl, (quinazolin-2-yl)methyl, (quinoxalin-6-yl)methyl, (4-methyl-quinazolin-2-yl)methyl, 2-cyano-benzyl, (3-cyano-quinolin-2-yl)methyl, (3-cyano-pyridin-2-yl)methyl, (4-methyl-pyrimidin-2-yl)methyl, or (4,6-dimethyl-pyrimidin-2-yl)methyl; and R2 is 3-(R)-amino-piperidin-1-yl, (2-amino-2-methyl-propyl)-methylamino, or (2-(S)-amino-propyl)-methylamino, or a pharmaceutically acceptable salt thereof.